Sylvester Comprehensive Cancer Center

  • 20231376 - Chauhan Aman

  • Investigator:
    Aman Chauhan
    RCname Email

    		Coordinator:

    IRB: 20231376

    		SDG: Thoracic
    Disease Site(s):

    Lung
    Sponsor: Alliance

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester
    UMH
    Title:

    Randomized Phase II Trial Of Lutetium Lu 177 Dotatate Versus Everolimus In Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
    Eligibility Criteria - NCT04665739 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210862 - Dawar Richa

  • Investigator:
    Richa Dawar
    RCname Email

    		Coordinator:

    IRB: 20210862

    		SDG: Thoracic
    Disease Site(s):

    Lung
    Sponsor: IB

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer
    Eligibility Criteria - NCT04614103 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220824 - Dawar Richa

  • Investigator:
    Richa Dawar
    RCname Email

    		Coordinator:

    IRB: 20220824

    		SDG: Thoracic
    Disease Site(s):

    Lung
    Sponsor: ETCTN

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
    Eligibility Criteria - NCT05198830 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240228 - Dawar Richa

  • Investigator:
    Richa Dawar
    RCname Email

    		Coordinator:

    IRB: 20240228

    		SDG: Thoracic
    Disease Site(s):

    Lung
    Sponsor: Genelux Corporation

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Pembrolizumab Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-Line Pembrolizumab-based Maintenance (VIRO-25 Study)
    Eligibility Criteria - NCT06463665 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240208 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    		Coordinator:

    IRB: 20240208

    		SDG: Thoracic
    Disease Site(s):

    Lung
    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
    Eligibility Criteria - NCT06096844 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210977 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:

    IRB: 20210977

    		SDG: Thoracic
    Disease Site(s):

    Multiple
    Sponsor: Nuvalent

    Enrolling Sites:

    Doral
    Sylvester
    Title:

    A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)
    Eligibility Criteria - NCT05118789 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230915 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:

    IRB: 20230915

    		SDG: Thoracic
    Disease Site(s):

    Lung,Non-Hodgkin Lymphoma
    Sponsor: Nuvalent

    Enrolling Sites:

    ABLEH
    Aventura
    Doral
    Gables
    Sylvester
    Title:

    A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
    Eligibility Criteria - NCT05384626 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240314 - Rodriguez Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    		Coordinator:

    IRB: 20240314

    		SDG: Thoracic
    Disease Site(s):

    Lung
    Sponsor: Roche-Genentech

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Divarasib Versus Sotorasib Or Adagrasib In Patients With Previously Treated KRAS G12C-Positive Advanced Or Metastatic Non-Small Cell Lung Cancer
    Eligibility Criteria - NCT06497556 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240640 - Watson Dionysios

  • Investigator:
    Dionysios Watson
    RCname Email

    		Coordinator:

    IRB: 20240640

    		SDG: Thoracic
    Disease Site(s):

    Lung
    Sponsor: Memorial Sloan-Kettering Cancer Center

    Enrolling Sites:

    ABLEH
    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A randomized phase II study of sotorasib versus continued consolidation durvalumab in patients with KRAS G12C mutant locally advanced non-small cell lung cancer (LA-NSCLC) with persistent ctDNA defined minimal residual disease
    Eligibility Criteria - NCT06333678 *This information has been extracted from " www.clinicaltrials.gov"